Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

definite multiple sclerosis."

"As a leader in multiple sclerosis treatments, we are committed to providing new options that can further improve the course of the disease and the quality of life for people living with this disease," said Dr. Richard Douge, Executive Vice President, Global Marketing, Merck Serono. "The initiation of the ORACLE MS study further demonstrates our commitment to continue to build a solid portfolio of products for use in a broad multiple sclerosis patient population. We believe that our proprietary oral formulation of Cladribine has the potential to address an important unmet medical need at a critical time of disease development."

The ORACLE MS study is a randomized, double-blind, placebo-controlled, international trial. It will involve more than 600 patients considered at risk of developing MS due to a recently experienced isolated demyelinating event (e.g. optic neuritis, myelopathy or brainstem syndrome) and having MRI brain scans consistent with early signs of MS. Study participants will be randomized in one of the three arms of the study to receive one of two different dosage regimens of Cladribine tablets or matching placebo tablets (1:1:1 ratio).

Patients will be treated for a period of two years (96 weeks), or up to the time when they experience a second attack leading to a diagnosis of clinically definite MS, in which case they would be offered open-label treatment with Rebif(R) 44 mcg three times a week for a 96-week maintenance treatment period. Patients who do not convert to clinically definite MS within the initial 96-week period of the study will be eligible to enroll in a 96- week long-term follow-up treatment period. These maintenance and long-term follow-up periods of the study are intended to assess the effect of early treatment with Cladribine tablets on relapses and subsequent treatment response to disease-modifying therapy for relapsing-remitting MS and to evaluate the sustained effect of Cladribi
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Decision Resources Group,s ... about by the Affordable Care Act (ACA), ... of pharmaceutical therapies. The ACA altered how ... new regulations and expanded access via government-supported ... health exchanges—state-based marketplaces set up by states ...
(Date:7/31/2014)... LISBON, Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval ... The inspection, carried out by the FDA Consumer Safety ... initially planned, started on 21 st July and concluded ... to be compliant with the principles and guidelines of Good ...
(Date:7/31/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), Gilead (Nasdaq: GILD - Free ... ), AbbVie (NYSE: ABBV - Free Report ) and ... Today, Zacks is promoting its ,Buy, stock recommendations. Get ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... Pharmaceutical Corporation (OTC Bulletin Board: PRTT ) announced ... and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company ... The patent portfolio includes innovative pain drugs that address the ... Protect,s Chief Operating Officer, said, "We are very happy to ...
... NEW YORK, Feb. 9, 2011 Reportlinker.com ... is available in its catalogue: ... and Vulnerable Plaque Treatment 2011 ... report details the responses of a comprehensive ...
Cached Medicine Technology:Protect Pharma Sells Patent Portfolio to Grunenthal GmbH 2Reportlinker Adds Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011 2
(Date:7/31/2014)... study published today in Genes & Development ... Sciences Centre,s DNA Replication group, in collaboration with ... intricate mechanisms involved in the enzyme that governs ... sophisticated system using synthetic, chemical and structural biology ... involved in duplicating genetic information embraces DNA through ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces the ... simplified and predictable with fixed fees across the board, ... international provider of legal discovery management services for law ... apparent that both the courts and legal counsel alike ... complex pricing structure that plagues the litigation support industry. ...
(Date:7/31/2014)... 2014 The Alaska Center for ... new dentist Dr. Jonathan Oudin, DDS, who will begin ... in Barrow, Alaska, for three years. According to Teresa ... Dr. Oudin to help take on new patients. , ... continue growing and serving the greater Anchorage metro community," ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Transplant surgeons often feel ... for burnout, a new study suggests. Nearly ... reported having a low sense of personal accomplishment ... emotionally exhausted, researchers found. "Burnout is common ... study co-author Dr. Marwan Abouljoud, director of the ...
(Date:7/31/2014)... algorithm aimed to diagnose pediatric patients with suspected ... scans, without affecting diagnostic accuracy, Mayo Clinic Children,s ... published in the journal Surgery . , ... acute abdominal pain in children. Appendicitis occurs when ... CT scans are often used to diagnose acute ...
Breaking Medicine News(10 mins):Health News:Molecular gate that could keep cancer cells locked up 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2
... to more false positives, additional work-ups , , THURSDAY, Jan. ... estimating glomerular filtration (eGFR) rates from routine blood work ... with chronic kidney disease, U.S. researchers report. , The ... kidneys over time, and its formula factors in measures ...
... BETHESDA, Md., Jan. 29 /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: ... of western healthcare,products and services in the People,s Republic ... third quarter 2009 financial results on Monday,February 9, 2009, ... 8:00 am ET that day to discuss financial results. ...
... Meditation technique may help keep discomfort at bay, study ... Zen meditation appears to reduce sensitivity to moderate pain ... "Previous studies had already shown that teaching patients with ... no one had examined how these effects might come ...
... management system designed to meet unique supply management ... Fla., Jan. 29 Omnicell, Inc. (Nasdaq: ... solutions to acute healthcare facilities, and Shands HealthCare ... chain management systems (formerly known as OptiFlex SS) ...
... and FORT LAUDERDALE, Fla., Jan. 29 Houlihan Smith,& ... into Tri-Tech Health, LLC, (Tri-Tech Health) as announced by,Charles ... The,advisory services were led by Houlihan Smith Managing ... , "We have been working ...
... Cholera Outbreak STAMFORD, Conn., Jan. 29 AmeriCares is ... in an effort to stem a deadly cholera outbreak ... outbreak is one of Africa,s deadliest in 15 years ... is at risk. With limited medical resources and dismal ...
Cached Medicine News:Health News:Kidney Function Test May Not Be Cost-Effective 2Health News:Chindex International, Inc. to Report Fiscal Third Quarter 2009 Financial Results 2Health News:The Zen Way to Pain Relief 2Health News:The Zen Way to Pain Relief 3Health News:The Zen Way to Pain Relief 4Health News:Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems 2Health News:Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems 3Health News:Houlihan Smith Arranges Equity Investment Into Tri-Tech Health, LLC 2Health News:AmeriCares Doubles Aid to Zimbabwe 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: